DCAF7 and pancreatic neuroendocrine tumor: A previous study has revealed that DCAF7 leads to resistance to the mTOR inhibitor everolimus in pancreatic neuroendocrine tumors.[18] However, there are currently no reports detailing the functional role of DCAF7 in tumor metastasis, and the precise biological function and molecular mechanisms of DCAF7 in the pathogenesis of NPC remain to be elucidated.